This year’s AASLD Conference will discuss the latest research on disease states like NAFLD, NASH, and Hepatitis. While educational sessions from leading hepatologists and public health experts will run alongside. Or delve deep with a niche session from one of the leading minds in the Meet-the-Expert sessions. The patient’s perspective will also be presented by the Patient Advocacy Group programming.
Will you be there too?
Head to our exhibition stand – #642
We look forward to meeting you to discuss how to improve the predictability of human toxicity using Organ-on-a-Chip. Reveal the mechanisms of drug-induced liver injury (DILI) with PhysioMimix™ OOC single-and multi-organ microphysiological systems.
Modeling the intestine-liver axis and the role of the FXR agonists in a multi-organ microphysiological system model of Non-Alcoholic Fatty Liver Disease
Microphysiological systems (MPS) are cutting-edge cell culture technologies that emulate the physiological microenvironment and functionality of human organs. Here we discuss how to rapidly and reliably integrate liver MPS into drug discovery and development workflows to gain translational pre-clinical data.
Date: Monday, November 7, 2022
Room: Poster Hall
Presentation from: Dr Tomasz Kostrzewski, CN Bio
Abstract number: 4310
Our Team at AASLD
Dr Tomasz Kostrzewski is VP – Science and Technology at CN Bio with more than 15 years of experience in molecular and cellular biology research. Prior to joining CN Bio, he worked at Imperial College London in the Department of Life Sciences studying immune cell development and stem cell differentiation. At Imperial College London he completed both an MRes and PhD in the department of Cell and Molecular Biology. He has significant experience in advanced (3D) mammalian cell culture, gene expression analysis and immune cell function. Additionally, he has previous experience of working in biopharmaceutical drug discovery and development with GlaxoSmithKline. In 2017, he was promoted to head of biology at CN Bio and is responsible for biological model development and collaborative research projects and in 2022 he took responsibility for all technical activities including developing new products, technologies and assays. TK has managed multiple grant-funded collaborative projects at CN Bio and is currently the project lead for the collaborative project between CN Bio and the FDA. TK has published more than twelve peer-reviewed scientific articles in the last five years and submitted several patent applications.